Trial reportThe British journal of radiology2020
BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial.
Trial report in The British journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Radiotherapy beam tracking by dual-modality injectable fiducial marker for X-ray CT and Cherenkov luminescence imaging.Biomedical optics express · 2026Article
- Preoperative marking of the proximal resection margin in esophageal cancer with a surgical fiducial marker: First experiences.World journal of methodology · 2025Article
- Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Clinical implementation of RTT-only CBCT-guided online adaptive focal radiotherapy for bladder cancer.Clinical and translational radiation oncology · 2025Article
- Minimizing human interference in an online fully automated daily adaptive radiotherapy workflow for bladder cancer.Radiation oncology (London, England) · 2024Article
- Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers.Radiation oncology (London, England) · 2023Article
- Endoscopically placed fiducial markers for image-guided radiotherapy in preoperative gastric cancer: Technical feasibility and potential benefit.Endoscopy international open · 2023Article
- Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.Frontiers in oncology · 2023Article
- Feasibility and guidelines for the use of an injectable fiducial marker (BioXmarkF1000Research · 2023Article
- BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial.Clinical and translational radiation oncology · 2023Article
- A liquid immunogenic fiducial eluter for image-guided radiotherapy.Frontiers in oncology · 2022Article
- Evaluation of computed tomography settings in the context of visualization and discrimination of low dose injections of a novel liquid soft tissue fiducial marker in head and neck imaging.BMC medical imaging · 2021Article
- MR-Guided Adaptive Radiotherapy for Bladder Cancer.Frontiers in oncology · 2021Review
- Exploratory models comparing ethiodized oil-glue and gold fiducials for bladder radiotherapy image-guidance.Physics and imaging in radiation oncology · 2021Article
- Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient out-comes.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluated the performance of the novel liquid fiducial marker (BioXmark®) in IGRT for bladder cancer.
methods20 patients with muscle invasive bladder cancer were entered in this prospective, single center, Phase I-II study. The novel BioXmark
resultsIn total, 76 markers were implanted in 20 patients. Of those, 60 (79% 95% CI ± 9%) were visible on CT scan. Due to the learning curve of the technique, the visibility improved in the last 75% of patients (86% visibility) compared to the first 25% of patients with 58% visibility. Concerning stability of the BioXmark
conclusionThe success rate of this novel fiducial marker was 79%, which is above the prospectively defined threshold rate. A distinct learning curve of the injection of the liquid marker was seen over the study period. The marker showed sustained visibility and positional stability during treatment phases and also appears to be safe and easy to inject. ADVANCES IN KNOWLEDGE: This novel liquid BioXmark® marker seems to be a very promising tool in daily-adaptive IGRT for bladder preserving chemoradiotherapy in muscle invasive bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.